In the oncology setting, MOSPD2 can be found histologically in many types of solid tumors, and it seems to be highly expressed on tumor cells when they start invading tissues or creating metastatic lesions. Our preliminary data indicate that knock-out of MOSPD2 in tumor cells may reduce metastasis by 95% in some pre-clinical settings.

We believe that targeting MOSPD2 may have several therapeutic applications, including inhibition of tumor cell metastases and killing of MOSPD2-positive tumor cells. VBL is developing various drug candidates, including bi-specific antibodies, towards this goal.

For additional information see our AACR 2018 poster: link and listen to a webcast from our recent presentation at BIO 2018: BIO 2018 Webcast link